Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
JCO Precis Oncol
2020 Jan 01;4. doi: 10.1200/PO.20.00200.
Show Gene links
Show Anatomy links
Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer.
Armstrong AJ
,
Luo J
,
Nanus DM
,
Giannakakou P
,
Szmulewitz RZ
,
Danila DC
,
Healy P
,
Anand M
,
Berry WR
,
Zhang T
,
Harrison MR
,
Lu C
,
Chen Y
,
Galletti G
,
Schonhoft JD
,
Scher HI
,
Wenstrup R
,
Tagawa ST
,
Antonarakis ES
,
George DJ
,
Halabi S
.
???displayArticle.abstract???
PURPOSE: Androgen receptor splice variant 7 (AR-V7) detection in circulating tumor cells (CTCs) is associated with a low probability of response and short progression-free (PFS) and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide or abiraterone. However, it is unclear whether such men benefit from taxane chemotherapy.
PATIENTS AND METHODS: PROPHECY is a multicenter prospective blinded study of patients with poor-risk mCRPC starting abiraterone or enzalutamide and observed through subsequent progression and taxane chemotherapy. We assessed AR-V7 status using the Johns Hopkins modified AdnaTest CTC AR-V7 messenger RNA assay and the Epic Sciences CTC nuclear-localized AR-V7 protein assay before treatment. The primary objective was to validate the independent prognostic value of CTC AR-V7 status based on radiographic/clinical PFS. OS, confirmed prostate-specific antigen (PSA), and objective radiologic responses were secondary end points.
RESULTS: We enrolled 118 men with mCRPC treated with abiraterone or enzalutamide, 51 of whom received subsequent docetaxel or cabazitaxel. Pretreatment CTC AR-V7 status by the Johns Hopkins and Epic Sciences assays was independently associated with worse PFS (hazard ratio [HR], 1.7; 95% CI, 1.0 to 2.9 and HR, 2.1; 95% CI, 1.0 to 4.4, respectively) and OS (HR, 3.3; 95% CI, 1.7 to 6.3 and HR, 3.0; 95% CI, 1.4 to 6.3, respectively) and a low probability of confirmed PSA responses, ranging from 0% to 11%, during treatment with abiraterone or enzalutamide. At progression, subsequent CTC AR-V7 detection was not associated with an inferior PSA or radiographic response or worse PFS or OS with subsequent taxane chemotherapy after adjusting for CellSearch CTC enumeration and clinical prognostic factors.
CONCLUSION: Detection of AR-V7 in CTCs by two different blood-based assays is independently associated with shorter PFS and OS with abiraterone or enzalutamide, but such men with AR-V7-positive disease still experience clinical benefits from taxane chemotherapy.
Abida,
Genomic correlates of clinical outcome in advanced prostate cancer.
2019, Pubmed,
Echinobase
Abida,
Genomic correlates of clinical outcome in advanced prostate cancer.
2019,
Pubmed
,
Echinobase
Aggarwal,
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.
2018,
Pubmed
Annala,
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.
2018,
Pubmed
Antonarakis,
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
2014,
Pubmed
Antonarakis,
Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
2015,
Pubmed
Antonarakis,
Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide.
2017,
Pubmed
Armenia,
The long tail of oncogenic drivers in prostate cancer.
2018,
Pubmed
Armstrong,
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.
2019,
Pubmed
Armstrong,
ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.
2019,
Pubmed
Arora,
Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade.
2013,
Pubmed
Beer,
Enzalutamide in metastatic prostate cancer before chemotherapy.
2014,
Pubmed
Beltran,
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.
2016,
Pubmed
Chakraborty,
Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression.
2020,
Pubmed
De Laere,
Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns.
2017,
Pubmed
De Laere,
TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer.
2019,
Pubmed
Eisenberger,
Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA.
2017,
Pubmed
Eisenhauer,
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
2009,
Pubmed
Fizazi,
Abiraterone in Metastatic Prostate Cancer.
2017,
Pubmed
Fizazi,
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
2019,
Pubmed
Grünwald,
Development of the epidermal growth factor receptor inhibitor OSI-774.
2003,
Pubmed
Halabi,
Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.
2014,
Pubmed
Halabi,
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.
2003,
Pubmed
Halabi,
Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy.
2013,
Pubmed
Henzler,
Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer.
2016,
Pubmed
Khalaf,
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
2019,
Pubmed
Kohli,
Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance.
2017,
Pubmed
Lokhandwala,
Analytical Validation of Androgen Receptor Splice Variant 7 Detection in a Clinical Laboratory Improvement Amendments (CLIA) Laboratory Setting.
2017,
Pubmed
Markowski,
Clinical Utility of CLIA-Grade AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer.
2017,
Pubmed
Morris,
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research.
2009,
Pubmed
Mu,
SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.
2017,
Pubmed
Noonan,
Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide.
2013,
Pubmed
Oudard,
Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.
2017,
Pubmed
Romanel,
Plasma AR and abiraterone-resistant prostate cancer.
2015,
Pubmed
Ryan,
Abiraterone in metastatic prostate cancer without previous chemotherapy.
2013,
Pubmed
Scher,
Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer.
2018,
Pubmed
Scher,
Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.
2016,
Pubmed
Scher,
Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer.
2015,
Pubmed
Scher,
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.
2016,
Pubmed
Scher,
Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer.
2017,
Pubmed
Schrader,
Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone.
2014,
Pubmed
Smith,
Apalutamide and Metastasis-free Survival in Prostate Cancer.
2018,
Pubmed
Sternberg,
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.
2020,
Pubmed
Tannock,
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
2004,
Pubmed
Wyatt,
Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.
2016,
Pubmed
de Bono,
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
2010,
Pubmed
de Bono,
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.
2008,
Pubmed
de Wit,
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
2019,
Pubmed
